PHARMACY

Teva announces availability of moxifloxacin hydrochloride tablets

BY Ryan Chavis

NORTH WALES, Pa. — Teva Pharmaceuticals announced the introduction of moxifloxacin hydrochloride tablets, the generic equivalent to Avelox tablets. The drug is available in 400-mg strength.

Moxifloxacin hydrochloride is used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria, the company said.

"Generic pharmaceuticals are playing an increasingly important role in healthcare cost containment," said Maureen Cavanaugh, SVP U.S. generics sales and marketing. "Teva Pharmaceuticals continues to lead the way with timely new product launches."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Momenta Pharmaceuticals’ Craig Wheeler named GPhA chairman

BY Michael Johnsen

ORLANDO, Fla. — The Generic Pharmaceutical Association on Wednesday announced that Craig Wheeler, president and CEO, Momenta Pharmaceuticals, was elected as GPhA board chairman. Wheeler succeeds Tony Mauro, president, Mylan North America. 

“I’m honored to be elected as chairman of GPhA’s board of directors,” Wheeler said. “Our member companies provide timely access to safe and affordable generic medicines for patients around the globe, putting treatment within reach for hundreds of millions of people. There are so many opportunities ahead for this dynamic industry, and I look forward to contributing to our shared success.”

“It is a time of extraordinary promise for our industry,” commented Ralph Neas, president and CEO of GPhA. “Patient safety remains our top priority as the Association leads efforts to preserve and promote access to generic medicines. Chairman Wheeler’s strong leadership will be pivotal as the industry works with the FDA, Congress and stakeholders at all levels of the health care system to improve labeling guidance, establish a framework for interchangeable biologic substitution, meet GDUFA goals and advocate for policies that encourage generic utilization at home and abroad.”  

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Kremers Urban launches rabeprazole sodium tablets

BY Ryan Chavis

PRINCETON, N.J. — Kremers Urban Pharmaceuticals, a subsidiary of UCB, announced the launch of rabeprazole sodium delayed-release tablets. The drug is used to treat gastroesophageal reflux disease in adults and adolescents, according to the FDA.

The product is the bioequivalent to Aciphex from Eisai. Kremers Urban rabeprazole sodium delayed-release tablets are available in 20-mg strength in both 30- and 90-count bottles.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?